Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.64 |
| ▸ | MME | P08473 | 3/20 | 0.53 |
| ▸ | ACE | P12821 | 2/20 | 0.53 |
| ▸ | ECE1 | P42892 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL489232 | 1.00 | MMEL1 (0.64) | MMEL1MMEACEECE1 | |
| Bromide SCHEMBL9683926 | 0.99 | MMEL1 (0.62) | MMEL1MMEACEECE1 | |
| SCHEMBL7316768 | 0.93 | MMEL1 (0.55) | MMEL1MMEACEECE1 | |
| SCHEMBL9682406 | 0.92 | MMEL1 (0.54) | MMEL1MMEACEECE1 | |
| SCHEMBL7343519 | 0.92 | MMEL1 (0.54) | MMEL1MMEACEECE1 | |
| SCHEMBL9683662 | 0.92 | MMEL1 (0.54) | MMEL1MMEACEECE1 | |
| SCHEMBL7310571 | 0.91 | MMEL1 (0.53) | MMEL1MMEACEECE1 | |
| SCHEMBL15202503 | 0.88 | L3MBTL1 (0.63) | MMEL1MMEACEECE1 | |
| SCHEMBL7319125 | 0.88 | MME (0.55) | MMEACEECE1 | |
| SCHEMBL7338163 | 0.87 | MMEL1 (0.49) | MMEL1MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 357 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1060182-B1 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS INC (US) | 2012-12-19 | — | — | EP | claimed |
| US-7351399-B2 | Prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. (US) | 2008-04-01 | — | — | US | claimed |
| US-20050288240-A1 | Novel-prodrugs for phosphorus-containing compounds | ERION MARK D | 2005-12-29 | — | — | US | claimed |
| EP-0511940-A2 | Phosphono/biaryl substituted dipeptide derivatives | CIBA-GEIGY AG (CH) | 1992-11-04 | — | — | EP | claimed |
| US-12351561-B2 | Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-07-08 | — | — | US | disclosed |
| US-20240327360-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2024-10-03 | — | — | US | disclosed |
| US-12016835-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240165032-A1 | DRUG DELIVERY SYSTEM | EB IP HYBRITABS B V (NL) | 2024-05-23 | — | — | US | disclosed |
| US-11919888-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-03-05 | — | — | US | disclosed |
| US-11851443-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230330028-A1 | PROCESS FOR THE PREPARATION OF DRUG DELIVERY SYSTEMS HAVING A TESTOSTERONE COMPOUND PRESENT IN AN OUTER LAYER OR PART, AS WELL AS SUCH DRUG DELIVERY SYSTEMS | EB IP HYBRITABS B.V. (NL) | 2023-10-19 | — | — | US | disclosed |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-05 | — | — | US | disclosed |
| WO-2000052015-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-1999045016-A9 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS INC (US) | 2000-03-02 | — | — | WO | disclosed |
| WO-1999045016-A2 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS, INC. (US) | 1999-09-10 | — | — | WO | disclosed |
| WO-1997011717-A1 | TREATMENT OF CHRONIC PROGRESSIVE RENAL FAILURE | NOVARTIS AG (CH) | 1997-04-03 | — | — | WO | disclosed |
| EP-0592367-A2 | Phosphono/biaryl substituted dipeptide derivatives | CIBA-GEIGY AG (CH) | 1994-04-13 | — | — | EP | disclosed |
| US-5294632-A | Diuretics and vasorelaxants | CIBA-GEIGY CORPORATION (US) | 1994-03-15 | — | — | US | disclosed |
| EP-0511940-A2 | Phosphono/biaryl substituted dipeptide derivatives | CIBA-GEIGY AG (CH) | 1992-11-04 | — | — | EP | disclosed |
| US-5155100-A | Treating cardiovascular disorders in mammals | CIBA-GEIGY CORPORATION (US) | 1992-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288240-A1 | Novel-prodrugs for phosphorus-containing compounds | HCRTR2, CYP2R1, SLC22A8 | MMEL1 2957/4885MME 4480/4885ACE 3667/4885 |
| US-12351561-B2 | Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof | MME, CTSC, REN | MMEL1 54/4885MME 1/4885ACE 4/4885 |
| US-20240327360-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | MME, CTSC, REN | MMEL1 54/4885MME 1/4885ACE 4/4885 |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MMEL1 240/4885MME 1/4885ACE 3/4885 |
| US-11851443-B2 | Neprilysin inhibitors | MME, REN, ACE | MMEL1 237/4885MME 1/4885ACE 3/4885 |
| US-12016835-B2 | Neprilysin inhibitors | MME, REN, ACE | MMEL1 213/4885MME 1/4885ACE 3/4885 |
| US-11919888-B2 | Neprilysin inhibitors | MME, REN, ACE | MMEL1 240/4885MME 1/4885ACE 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.